STAGE 4 OVARIAN
CANCER TREATMENT
PARP inhibitor maintenance changed the trajectory of advanced ovarian cancer treatment for BRCA-mutated patients. BRCA and HRD testing at diagnosis determines who qualifies for the most impactful maintenance option.
Advanced Ovarian Cancer Treatment Framework
| Setting | Treatment | Key Notes |
|---|---|---|
| First-line chemotherapy | Carboplatin plus paclitaxel (6 cycles) +/- bevacizumab | Bevacizumab continuation as maintenance if included first-line |
| First-line maintenance: BRCA-mutated | Olaparib (SOLO-1) | Median PFS >36 months. Most impactful maintenance option. Testing before chemotherapy starts is critical. |
| First-line maintenance: HRD-positive (non-BRCA) | Niraparib (PRIMA) or olaparib plus bevacizumab (PAOLA-1) | Benefit meaningful but smaller than BRCA-mutated group |
| First-line maintenance: HRD-negative, non-BRCA | Bevacizumab or observation | Limited PARP inhibitor benefit in standard settings |
| Platinum-sensitive recurrence | Platinum re-treatment + PARP inhibitor at recurrence for BRCA-mutated | Recurrence >6 months after platinum completion |
| Platinum-resistant recurrence | Non-platinum single agents; bevacizumab combination; clinical trials priority | Recurrence within 6 months of platinum. Limited options -- trials appropriate. |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Stage 4 Ovarian Cancer Treatment?
CancerFax reviews your BRCA and HRD status to assess PARP inhibitor eligibility and connects you with gynaecologic oncologists experienced in advanced ovarian cancer.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.